Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China

• Main Authors: Hong-Shuai Li (Author), Guang-Jian Yang (Author), Yi Cai (Author), Jun-Ling Li (Author), Hai-Yan Xu (Author), Tao Zhang (Author), Li-Qiang Zhou (Author), Yu-Ying Wang (Author), Jin-Liang Wang (Author), Xing-Sheng Hu (Author), Xiang Yan (Author), Yan Wang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on major uncommon EGFR mutations is currently limited.Materials and methods: This was a dual-cent...